Yu-Xiao Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yu-Xiao Yang has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Kevin Haynes
Department of Medicine and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
15 shared publicationsBen Boursi
Department of Medicine and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; Tel-Aviv University, Tel-Aviv, Israel
14 shared publicationsRonac Mamtani
Department of Medicine and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
14 shared publications- Ben Boursi
Department of Oncology, Sheba Medical Center, Tel-Hashomer , Tel-Aviv, ; , Tel-Aviv
7 shared publications James D. Lewis
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
6 shared publications- Kevin Haynes
HealthCore
6 shared publications
Latest Publications
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , e16226
A clinical prediction model to assess risk for pancreatic cancer among patients with pre-diabetes.
E16226 Background: A new diagnosis of diabetes mellitus (DM) has been observed within 2-3 years before the clinical presentation of a substantial proportion of sporadic pancreatic ductal adenocarcinoma (PDA) cases. The objective of the current study was to develop and internally validate a clinical prediction model for 3-year PDA risk among individuals with pre-diabetes defined as newly detected impaired fasting glucose (IFG). Methods: The study was conducted using the Health Improvement Network (THIN), a population-representative general practice medical records database from the UK. Eligible patients were aged ≥35 years, had a newly diagnosed IFG during follow-up and had ≥ 3 years of follow-up following the diagnosis of IFG. The dependent variable was incident PDA diagnosed within 3 years of IFG diagnosis. We evaluated a comprehensive list of PDA risk factors as well as variables related to glucose metabolism and performed multiple imputation for candidate predictors with missing values. We selected predictors using univariable analysis and a backward stepwise approach. A bootstrapping procedure was used for internal validation. Results: We identified 138,232 eligible patients with new-onset IFG. Among this cohort, 245 individuals (0.2%) were diagnosed with PDA within 3 years of IFG diagnosis. The median follow-up from IFG detection to PDA diagnosis was 326 days (IQR 120-588). The full multivariable prediction model included age, BMI, PPIs, total cholesterol, LDL, ALT and alkaline phosphatase. The AUC of the model was 0.71 (95%CI 0.67-0.75), and the p-value for the Hosmer and Lemeshow goodness of fit test was > 0.05. Internal validation of the model using bootstrapping procedure revealed minimal optimism of 0.001 (95%CI -0.009-0.01). Conclusions: We developed and internally validated a PDA prediction model based on clinical information routinely available at the initial appearance of IFG. This model exhibited good discrimination and calibration. The current model may substantially extend our ability to detect subclinical PDAs at an earlier stage when the tumor may potentially be more amenable to curative resection.
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , e16226
A clinical prediction model to assess risk for pancreatic cancer among patients with pre-diabetes.
E16226 Background: A new diagnosis of diabetes mellitus (DM) has been observed within 2-3 years before the clinical presentation of a substantial proportion of sporadic pancreatic ductal adenocarcinoma (PDA) cases. The objective of the current study was to develop and internally validate a clinical prediction model for 3-year PDA risk among individuals with pre-diabetes defined as newly detected impaired fasting glucose (IFG). Methods: The study was conducted using the Health Improvement Network (THIN), a population-representative general practice medical records database from the UK. Eligible patients were aged ≥35 years, had a newly diagnosed IFG during follow-up and had ≥ 3 years of follow-up following the diagnosis of IFG. The dependent variable was incident PDA diagnosed within 3 years of IFG diagnosis. We evaluated a comprehensive list of PDA risk factors as well as variables related to glucose metabolism and performed multiple imputation for candidate predictors with missing values. We selected predictors using univariable analysis and a backward stepwise approach. A bootstrapping procedure was used for internal validation. Results: We identified 138,232 eligible patients with new-onset IFG. Among this cohort, 245 individuals (0.2%) were diagnosed with PDA within 3 years of IFG diagnosis. The median follow-up from IFG detection to PDA diagnosis was 326 days (IQR 120-588). The full multivariable prediction model included age, BMI, PPIs, total cholesterol, LDL, ALT and alkaline phosphatase. The AUC of the model was 0.71 (95%CI 0.67-0.75), and the p-value for the Hosmer and Lemeshow goodness of fit test was > 0.05. Internal validation of the model using bootstrapping procedure revealed minimal optimism of 0.001 (95%CI -0.009-0.01). Conclusions: We developed and internally validated a PDA prediction model based on clinical information routinely available at the initial appearance of IFG. This model exhibited good discrimination and calibration. The current model may substantially extend our ability to detect subclinical PDAs at an earlier stage when the tumor may potentially be more amenable to curative resection.
- 1 June 2017
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 15 (6) , 953-954
Lactulose Is Associated With Decreased Risk of Clostridium difficile Infection in Decompensated Cirrhosis
- 1 June 2017
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 15 (6) , 953-954
Lactulose Is Associated With Decreased Risk of Clostridium difficile Infection in Decompensated Cirrhosis
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 1562
The association between proton pump inhibitors (PPI) use for gastro-esophageal reflux disease (GERD) and lung cancer (LC): A nested case-control study.
1562 Background: Data suggests that GERD with recurrent reflux and microaspiration of stomach contents, may be associated with lung injury, inflammation, activation of proliferative signals, and eventually DNA damage and malignant transformation. Recently, a large population based cohort study found that GERD may increase the risk of lung cancer in Asians. In the present nested case control study, we aimed to evaluate the association between PPI use as a surrogate for GERD and lung cancer in a large western population. Methods: We conducted a matched case-control study within a population-representative database from the United Kingdom. Study cases were defined as individuals with any diagnostic code of lung cancer. For every case, four eligible controls were matched on age, gender, practice site, time and duration of follow-up. Exposure of interest was PPI use prior to cancer diagnosis. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for lung cancer were estimated using conditional logistic regression. Adjustment was performed for smoking. Results: The study population included 19143 lung cancer cases and 74473 matched controls. PPI use was associated with a significantly increased lung cancer risk (adjusted OR 1.70, 95%CI 1.64-1.77, p < 0.001). In a sensitivity analyses we observed similar associations when PPI use was initiated more than one year prior to cancer diagnosis (adjusted OR 1.18, 95%CI 1.13-1.23, p < 0.001) and more than two years prior to cancer diagnosis (adjusted OR 1.15, 95%CI 1.10-1.20, p < 0.001) Conclusions: ChronicPPI use, as a surrogate for symptomatic GERD, may be associated with a higher lung cancer risk.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 1562
The association between proton pump inhibitors (PPI) use for gastro-esophageal reflux disease (GERD) and lung cancer (LC): A nested case-control study.
1562 Background: Data suggests that GERD with recurrent reflux and microaspiration of stomach contents, may be associated with lung injury, inflammation, activation of proliferative signals, and eventually DNA damage and malignant transformation. Recently, a large population based cohort study found that GERD may increase the risk of lung cancer in Asians. In the present nested case control study, we aimed to evaluate the association between PPI use as a surrogate for GERD and lung cancer in a large western population. Methods: We conducted a matched case-control study within a population-representative database from the United Kingdom. Study cases were defined as individuals with any diagnostic code of lung cancer. For every case, four eligible controls were matched on age, gender, practice site, time and duration of follow-up. Exposure of interest was PPI use prior to cancer diagnosis. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for lung cancer were estimated using conditional logistic regression. Adjustment was performed for smoking. Results: The study population included 19143 lung cancer cases and 74473 matched controls. PPI use was associated with a significantly increased lung cancer risk (adjusted OR 1.70, 95%CI 1.64-1.77, p < 0.001). In a sensitivity analyses we observed similar associations when PPI use was initiated more than one year prior to cancer diagnosis (adjusted OR 1.18, 95%CI 1.13-1.23, p < 0.001) and more than two years prior to cancer diagnosis (adjusted OR 1.15, 95%CI 1.10-1.20, p < 0.001) Conclusions: ChronicPPI use, as a surrogate for symptomatic GERD, may be associated with a higher lung cancer risk.
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S274-S275
A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients with New-Onset Diabetes Mellitus
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S274-S275
A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients with New-Onset Diabetes Mellitus
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1122-S1123
Sustained Post-Transplant Diabetes is Associated with an Increased Risk of Major Cardiovascular Events Following Liver Transplantation
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1122-S1123
Sustained Post-Transplant Diabetes is Associated with an Increased Risk of Major Cardiovascular Events Following Liver Transplantation
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S896
Total Serum Cholesterol and Pancreatic Cancer: A Nested Case-Control Study
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S896
Total Serum Cholesterol and Pancreatic Cancer: A Nested Case-Control Study
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S496
The Influence of Proton Pump Inhibitors on Pancreatic Cancer Risk and Survival after Diagnosis
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S496
The Influence of Proton Pump Inhibitors on Pancreatic Cancer Risk and Survival after Diagnosis
- 11 March 2017
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 62 (5) , 1295-1304
A Novel Model for Predicting Incident Moderate to Severe Anemia and Iron Deficiency in Patients with Newly Diagnosed Ulcerative Colitis
Background Anemia and iron deficiency are common complications of ulcerative colitis (UC). We aimed to develop and internally validate a prediction model for the incidence of moderate to severe anemia and iron deficiency anemia (IDA) in newly diagnosed patients with UC. Methods Multivariable logistic regression was performed among a nationwide cohort of patients who were newly diagnosed with UC in the VA health-care system. Model development was performed in a random two-third of the total cohort and then validated in the remaining one-third of the cohort. As candidate predictors, we examined routinely available data at the time of UC diagnosis including demographics, medications, laboratory results, and endoscopy findings. Results A total of 789 patients met the inclusion criteria. For the outcome of moderate to severe anemia, age, albumin level and mild anemia at UC diagnosis were predictors selected for the model. The AUC for this model was 0.69 (95% CI 0.64–0.74). For the outcome of moderate to severe anemia with evidence of iron deficiency, the predictors included African-American ethnicity, mild anemia, age, and albumin level at UC diagnosis. The AUC was 0.76, (95% CI 0.69–0.82). Calibration was consistently good in all models (Hosmer–Lemeshow goodness of fit p > 0.05). The models performed similarly in the internal validation cohort. Conclusions We developed and internally validated a prognostic model for predicting the risk of moderate to severe anemia and IDA among newly diagnosed patients with UC. This will help identify patients at high risk of these complications, who could benefit from surveillance and preventive measures.
- 11 March 2017
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 62 (5) , 1295-1304
A Novel Model for Predicting Incident Moderate to Severe Anemia and Iron Deficiency in Patients with Newly Diagnosed Ulcerative Colitis
Background Anemia and iron deficiency are common complications of ulcerative colitis (UC). We aimed to develop and internally validate a prediction model for the incidence of moderate to severe anemia and iron deficiency anemia (IDA) in newly diagnosed patients with UC. Methods Multivariable logistic regression was performed among a nationwide cohort of patients who were newly diagnosed with UC in the VA health-care system. Model development was performed in a random two-third of the total cohort and then validated in the remaining one-third of the cohort. As candidate predictors, we examined routinely available data at the time of UC diagnosis including demographics, medications, laboratory results, and endoscopy findings. Results A total of 789 patients met the inclusion criteria. For the outcome of moderate to severe anemia, age, albumin level and mild anemia at UC diagnosis were predictors selected for the model. The AUC for this model was 0.69 (95% CI 0.64–0.74). For the outcome of moderate to severe anemia with evidence of iron deficiency, the predictors included African-American ethnicity, mild anemia, age, and albumin level at UC diagnosis. The AUC was 0.76, (95% CI 0.69–0.82). Calibration was consistently good in all models (Hosmer–Lemeshow goodness of fit p > 0.05). The models performed similarly in the internal validation cohort. Conclusions We developed and internally validated a prognostic model for predicting the risk of moderate to severe anemia and IDA among newly diagnosed patients with UC. This will help identify patients at high risk of these complications, who could benefit from surveillance and preventive measures.
- 2 March 2017
- Published by Wiley in European Journal of Cancer Care
- Vol. 27 (1) , e12666
Chronic therapy with selective serotonin reuptake inhibitors and survival in newly diagnosed cancer patients
Depression might be associated with shorter disease specific survival. Selective serotonin reuptake inhibitors (SSRIs) were previously reported to increase the risk of certain malignancies. We aimed to evaluate the impact of SSRIs on cancer mortality. Five retrospective cohort studies were conducted in a UK population-representative database that included all individuals with an incident diagnosis of melanoma, breast, prostate lung and colorectal cancer. The primary exposure of interest was continuous use of SSRIs with past use as the comparison reference. Cox regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI). The study included 5,591 newly diagnosed cancer patients. Continuous SSRI use was associated with lower survival compared to past users for melanoma, breast, prostate, lung and colorectal cancers with HRs for the risk of death of 2.02 (95% CI 1.24–3.28), 1.91 (95% CI 1.53–2.38), 1.79 (95% CI 1.38–2.33), 1.44 (95% CI 1.19–1.75) and 1.51 (95% CI 1.21–1.72) respectively. The incidence of death during the first 2 years following cancer diagnosis associated with continuous SSRI use were elevated for breast (1.72, 95% CI 1.30–2.27), prostate (1.64, 95% CI 1.20–2.24) and lung cancers (1.45, 95% CI 1.26–1.66). In conclusion, continuous use of SSRIs might be associated with lower survival in cancer patients.
- 2 March 2017
- Published by Wiley in European Journal of Cancer Care
- Vol. 27 (1) , e12666
Chronic therapy with selective serotonin reuptake inhibitors and survival in newly diagnosed cancer patients
Depression might be associated with shorter disease specific survival. Selective serotonin reuptake inhibitors (SSRIs) were previously reported to increase the risk of certain malignancies. We aimed to evaluate the impact of SSRIs on cancer mortality. Five retrospective cohort studies were conducted in a UK population-representative database that included all individuals with an incident diagnosis of melanoma, breast, prostate lung and colorectal cancer. The primary exposure of interest was continuous use of SSRIs with past use as the comparison reference. Cox regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI). The study included 5,591 newly diagnosed cancer patients. Continuous SSRI use was associated with lower survival compared to past users for melanoma, breast, prostate, lung and colorectal cancers with HRs for the risk of death of 2.02 (95% CI 1.24–3.28), 1.91 (95% CI 1.53–2.38), 1.79 (95% CI 1.38–2.33), 1.44 (95% CI 1.19–1.75) and 1.51 (95% CI 1.21–1.72) respectively. The incidence of death during the first 2 years following cancer diagnosis associated with continuous SSRI use were elevated for breast (1.72, 95% CI 1.30–2.27), prostate (1.64, 95% CI 1.20–2.24) and lung cancers (1.45, 95% CI 1.26–1.66). In conclusion, continuous use of SSRIs might be associated with lower survival in cancer patients.
- 1 March 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (4) , 840-850.e3
A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes
- 1 March 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (4) , 840-850.e3
A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes